Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Conditions: B-Cell Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic Interventions: Biological: Autologous HuCD19 ( Anti-CD19)CAR T cells; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Rituximab Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Conditions: High Titers of Anti-HLA Antibody (MFI ≥5000) Interventions: Combination Product: Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG Sponsors: Anhui Provincial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL
Conditions: Mantle Cell Lymphoma Interventions: Drug: Orelabrutinib; Drug: Bendamustine Injection; Drug: Rituximab; Drug: Orelabrutinib Placebo Sponsors: InnoCare Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
Conditions: Chronic Lymphocytic Leukemia Sponsors: AbbVie Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Conditions: Large B-cell Lymphoma Interventions: Drug: Golcadomide; Drug: Placebo; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone Sponsors: Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Conditions: Follicular Lymphoma; Marginal Zone Lymphoma; B-Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; BeiGene, Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
Conditions: Ocular Myasthenia Gravis Interventions: Drug: immediate treatment with corticosteroids; Drug: addition of rituximab if recurrence Sponsors: Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Conditions: Membranous Nephropathy Interventions: Drug: RiTUXimab Injection Sponsors: Centre Hospitalier Universitaire de Nice Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Conditions: Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Mosunetuzumab; Procedure: Positron Emission Tomography; Biological: Rituximab; Biological: Rituximab and Hyaluronidase Human Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Ma-Spore ALL 2020 Study
Conditions: B Lymphoblastic Leukemia Interventions: Drug: Prednisolone; Drug: Dexamethasone; Drug: Vincristine; Drug: Methotrexate; Drug: L-Asparaginase; Drug: Pegylated asparaginase; Drug: Erwinase; Drug: Dasatinib; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Thioguanine; Drug: Rituximab; Drug: Doxorubicin; Drug: Fludarabine Sponsors: National University Hospital, Singapore Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Interventions: Drug: Rituximab Sponsors: Istituto Clinico Humanitas; IRCCS National Neurological Institute " C. Mondino " Foundation Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV
Conditions: Vasculitis Interventions: Drug: Avacopan Sponsors: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Conditions: CLL/SLL Interventions: Drug: Lisaftoclax (APG-2575); Drug: Acalabrutinib; Drug: Fludarabine; Drug: Cyclophosphamide ，CTX; Drug: Rituximab; Drug: Chlorambucil Sponsors: Ascentage Pharma Group Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Conditions: Relapsed or Refractory Follicular Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Rituximab; Drug: Prednisone; Drug: Bendamustine; Drug: Lenalidomide; Drug: Fludarabine; Drug: Liso-cel Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
